SC
TSHA icon

Steven Cohen’s Taysha Gene Therapies TSHA Stock Holding History

Steven Cohen’s Portfolio TSHA Stock Details TSHA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-461,856
Closed -$2.06M – 4592
2026
Q1 		$2.06M Sell
461,856
-3,406,826
-88% -$15.8M ﹤0.01% 2283
2025
Q4 		$21.3M Sell
3,868,682
-3,462,788
-47% -$16.8M 0.02% 846
2025
Q3 		$24M Buy
7,331,470
+13,856
+0.2% +$39.2K 0.04% 494
2025
Q2 		$16.9M Buy
7,317,614
+2,747,936
+60% +$5.97M 0.03% 561
2025
Q1 		$6.35M Buy
+4,569,678
New +$7.64M 0.01% 843
2024
Q2 		– Sell
-1,113,232
Closed -$3.19M – 2455
2024
Q1 		$3.19M Sell
1,113,232
-1,574,768
-59% -$3.28M 0.01% 1112
2023
Q4 		$4.76M Buy
2,688,000
+1,751,450
+187% +$3.49M 0.01% 946
2023
Q3 		$2.96M Buy
+936,550
New +$1.75M 0.01% 1036
2021
Q1 		– Sell
-13,366
Closed -$355K – 1183
2020
Q4 		$355K Sell
13,366
-186,634
-93% -$4.02M ﹤0.01% 856
2020
Q3 		$4.48M Buy
+200,000
New +$4.7M 0.02% 585

Other funds holding TSHA

ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Steven Cohen's TSHA Position: Q2 2026 in Review

Steven Cohen sold out of Taysha Gene Therapies (TSHA) in Q2 2026, closing a stake of 461,856 shares — an estimated $2.06M sold.

Steven Cohen first reported a position in TSHA in Q3 2020 and held it in 10 quarters. The position peaked at $24M in Q3 2025. 208 funds tracked by Wall St. Rank hold TSHA as of Q2 2026.

  • Steven Cohen reported no remaining Taysha Gene Therapies position as of Q2 2026 after selling out during the quarter.
  • Steven Cohen sold 461,856 Taysha Gene Therapies shares in Q2 2026, an estimated $2.06M.
  • Steven Cohen first reported a position in Taysha Gene Therapies in Q3 2020 and held it in 10 quarters.
  • Steven Cohen's Taysha Gene Therapies position peaked at $24M in Q3 2025.
  • 208 funds tracked by Wall St. Rank held Taysha Gene Therapies as of Q2 2026.

Based on Point72 Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.